Weighted-Average Shares Outstanding (Diluted): The number of shares held by shareholders including insiders but not including a company's treasury shares assuming conversion of all convertible debt, securities, warrants and options, sourced from the company 10-K or 10-Q SEC reports.
Skye Bioscience, Inc. (SKYE) had Weighted-Average Shares Outstanding (Diluted) of 39.67M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
-- |
|
$-12.75M |
|
-- |
|
-- |
|
$13.26M |
|
$-13.26M |
|
$0.51M |
|
$-12.75M |
|
$-12.85M |
|
$-12.75M |
|
$-12.75M |
|
$-12.75M |
|
$-12.85M |
|
$-13.26M |
|
$-13.09M |
|
39.67M |
|
|
Weighted-Average Shares Outstanding (Diluted) |
39.67M |
$-0.32 |
|
$-0.32 |
|
| Balance Sheet Financials | |
$39.92M |
|
$1.03M |
|
$1.40M |
|
$41.32M |
|
$8.37M |
|
-- |
|
$0.12M |
|
$8.49M |
|
$32.84M |
|
$32.84M |
|
$32.84M |
|
30.99M |
|
| Cash Flow Statement Financials | |
$-33.30M |
|
$-16.70M |
|
$0.02M |
|
$68.42M |
|
$18.44M |
|
$-49.97M |
|
$6.15M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.77 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-33.12M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-38.84% |
|
-38.84% |
|
-30.86% |
|
-38.84% |
|
$1.06 |
|
$-0.83 |
|
$-0.84 |
|